Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

Similar documents
AXITAB-CV TAB. COMPOSITION :

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Other β-lactam. A. Carbapenems:

STRUCTURE OF COMMONLY USED PENICILLINS

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

CLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Vancomycin: Class: Antibiotic.

Sep Oct Nov Dec Total

number Done by Corrected by Doctor مالك الزحلف

ICU Volume 11 - Issue 3 - Autumn Series

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

MCQ S. 1. Which of the following could be given to someone who had an allergy to sulphonamides previously:

Aciphin Ceftriaxone Sodium

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Vancomycin. A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci.

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

ESCMID Online Lecture Library. by author

Anaerobes Bacteroides species, Clostridium species (Note: most strains of C.difficile are resistant).

life-threatening infections

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

Roland Solensky, MD, FAAAAI. The Corvallis Clinic Corvallis, OR

Mesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections

A Retrospective Cross- sectional Study Evaluating Beta- lactam Allergy Labeling in Hospitalized Patients

PHARMACOLOGY II. Dr Shariq Syed Associate Professor AIKTC, SoP

Inpatient Beta-lactam Allergy Guideline

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005

Macrolides, Clindamycin & Ketolides Polymyxins

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate

Beta lactam Allergies Facts vs. Fears

Penicillin Allergy and Use of Other Antibiotics

Cases in employees. Cases. Day of onset (July)

Expert rules in antimicrobial susceptibility testing: State of the art

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Successful treatment of pan - resistant pseudomonas Aerugınosa menıngıtıs wıth ıntrathecal polymyxın b therapy

PACKAGE INSERT USP ANTIBIOTIC

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

Therapeutic drug monitoring of β-lactams

Aminoglycosides. Not orally absorbed. Interact with negatively charged lipopolysaccharide on Gram- cell wall. Aminoglycoside properties

Rapid identification and resistance assessment: The future is mass spectrometry

PREAMBLE. I m here to give you feedback on your prescribing

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

SEMINAR ON ACUTE BACTERIAL MENINGITIS AND ANTI MICROBIALS IN NEURO SURGERY. Presented By : DR. ROHIT K GOEL

Treatment of febrile neutropenia in patients with neoplasia

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Protein Synthesis Inhibitors

Anti-Microbial Drugs

β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication

Vancomycin Orion , Version 2 Public Summary of the Risk Management Plan

MERREM IV. meropenem PRODUCT INFORMATION COOH CH 3

Issues Abx request. Sneezing w/ post- nasal d/c & redness mucous membranes Throat. Chest px w/ coughing, difficulty breathing

PRODUCT INFORMATION Vancomycin Alphapharm Vancomycin hydrochloride NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Structural formula:

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

Summary of Product Characteristics

HUSRES Annual Report 2009 Martti Vaara

Initiating Aminoglycosides Safely. Last updated: July 2016, Version 5 Questions/Comments?

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

Update on CLSI and EUCAST

Medicine - Dr. Hawar - Lecture 5 - CNS Infections I

AMINOGLYCOSIDES TDM D O N E B Y

Amoxitid 125 Suspension Each teaspoonful (5 ml) contains Amoxicillin (as trihydrate) 125 mg.

Endocardite infectieuse

Protein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Preventing & Controlling the Spread of Infection

College of Pharmacy Advanced Clinical Pharmacology Spring 2013 Semester. Antibiotics PCN. Danita 1 Dee Narciso Pharm D

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Vancomycin Alphapharm

Ceftizoxime in the treatment of infections in patients with cancer

Vancomycin Injection, USP

FAROBACT 200 Tablets (Faropenem)

by author ESCMID Online Lecture Library

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Beta-Lactam Use in Penicillin Allergic Patients Clinical Guideline

CAVIWIPES1. Technical Bulletin

Mechanisms of Daptomycin Resistance and the Seesaw Effect in Multi-Drug Resistant Enterococci. NAME OF STUDENT Candidacy Exam August 25, 2017

Acute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

PK/PD degli antibiotici utilizzati nella sepsi

Overview. Clinical Scenario. Endocarditis: Treatment & Prevention. Prophylaxis The Concept. Jeremy D. Young, MD, MPH. Division of Infectious Diseases

MERREM IV (meropenem for injection), for intravenous use Initial U.S. Approval: weeks GA and PNA less than 2 weeks

A Novel Lantibiotic Acting on Bacterial Cell Wall Synthesis Produced by the Uncommon FLAVIA MARINELLI. DBSM, University of Insubria, Varese Italy

VANCOCIN CAPSULES (vancomycin hydrochloride)

Public Health Surveillance for Multi Drug Resistant Organisms in Orange County

CRIFOS 4 GM Injection (Fosfomycin sodium)

Aminoglycosides John A. Bosso, Pharm.D.

Antibiotic Treatment of Adults With Infective Endocarditis Due to Streptococci, Enterococci, Staphylococci, and HACEK Microorganisms

Penicillin Allergy Edition December 11 th, 2018

Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)

COONa CH 2 OCOCH 3 CONH H

PEDIATRIC PHARMACOTHERAPY

Antimicrobial resistance and virulence genes in bacteria

Consequences for the clinicians

Transcription:

Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties Stability to bacterial enzymes Generations - in response to clinical needs First generation - Cephalothin (not used) Cefazolin oral - Cephalexin, cefaclor Activity - Broad spectrum: Gram positive Streptococci, S. aureus Gram negative - E.coli, Klebsiella No activity against Enterococci - different PBP s Cephalosporins Development - Giuseppe Brodtzu - Sardinian sewage Cephalosporin C - Cephalothin No meningeal penetration Failed in meningococcal meningitis Painful to give IM Advantages Cephalosporin nucleus - resistant to Staphylococcal penicillinase Cephalosporin nucleus - more readily modified Cefuroxime Cefoxitin Cefotetan Second generation C sporins 70 s - Beta-lactamase s recognized (H. influenzae) Anaerobic infections Cefoxitin - Methoxy group - conferred beta-lactamase stability Induction of chromosomal beta-lactamases Bacteroides fragilis - enteric anaerobes Cefuroxime - Respiratory tract infections - community acquired 1

Third generation C sporins 80 s - Intensive care - nosocomial infections Multi-Resistant Gram negative organisms Chromosomal beta-lactamase - C sporinase Inducible Plasmid mediated enzymes - mutants with both Penicillinase and C sporinase activity Permeability limitations Kinetics of c sporin binding Affinity for receptor - PBP Permeability characteristics of the porin Beta-lactamase production - within periplasmic space Third generation c sporins Cefotaxime Ceftriaxone Ceftazidime Cefipime Highly active - Cefotaxime - S. pneumo N. meningitidis, gets across BBB Ceftriaxone - even more active - Single dose IM get meningeal levels - Long half life!!! N. gonorrhoeae, use in unreliable patients - Cover S. pneumonia bacteremia Use in meningitis - 2

Ceftazidime/Cefepime - anti- Pseudomonas Used the side groups which have increased permeability through P.aeruginosa porins - Cefepime Fourth generation Increased beta-lactamase stability Also better Gram positive -? Induction (low level) of chromosomal C sporinase Beta-lactamase stable - less activity against gram positive organisms 3

Carbapenems Imipenem Meropenem Beta-lactam class - PBP-2 major target Permeability - separate porin Huge spectrum - Aerobes, anaerobes everything EXCEPT Enterococci Stenotrophomonas etc. Concern - CNS side effects - Imipenem?? Use of the cephalosporins: First generation - Oral - surgical prophylaxis - skin soft tissue infections - taste good - house cephalosprorin Second generation - Some oral - some parenteral Selected uses Parenteral - Third generation Increased - due to resistant S. pneumoniae - susceptible to cefotaxime and ceftriaxone Gram negative infections - hospital acquired - selection of resistant organisms Monobactams - Aztreonam Only binds to Gram negative PBP s No real beta-lactam ring - therefore beta-lactamase stable Narrow spectrum - Only aerobic gram negative rods Use - instead of an aminoglycoside Pharmacology Charged - hydrophilic - do not enter phagocytic cells Variably protein bound (Ceftriaxone - highly bound) Variable half-lives Metabolism - Cefotaxime - Liver - desacetyl derivative - active Excretion - Renal - Tubular secretion and glomerular filtration 4

Beta-lactams side effects penicillin c sporin cross reactivity 3-7% (depending on the drug) Hypersensitivity Rash IgE-mediated allergy Anaphylaxis Major determinants minor side effects Minor determinants MAJOR reactions Diarrhea Neutropenia CNS high doses - especially the carbapenems C sporins Intrinsic resistance - enterococci - different targets Acquired resistance - active change Acquisition of an enzyme Induction of an enzyme Selection of a mutation Alteration in permeability Vancomycin History - Developed in the 50 s - anti-staph drug Re- discovered - MRSA - and MRSE - Staphylococci with altered PBP-2A meca gene - no longer binds penicillin (C sporins don t bind either) Target - D-ala-D-ala - pentapeptide blocks two steps in cell wall synthesis Cidal - Only gram positives - Highly resistant S. pneumo 5

Vancomycin - properties Small glycoprotein (MWt @ 1,450) derived from Nocardia orientalis Activity - most G(+) bacteria including Streptococci, Corynebacteria, Clostridia, Listeria, and Bacillus species. Bactericidal at levels 0.5-3 mg/l Staphylococci including ß-lactamase producing and methicillin resistant species are killed at levels <10 mg/l Vancomycin and Resistant S. pneumoniae Penicillin MIC s <0.1 - S; 0.1-1= RR; >2.0 Resistant Alternate therapy - Pneumonia/Bacteremia - Cefotaxime or Ceftriaxone? Meningitis - Can t achieve levels - Vancomycin - high doses - gets into CSF Resistance - vancomycin resistant enterococcus (VRE) Vancomycin - Pharamacokinetic properties Vancomycin resistant enterococci Vd @ 0.7 L/kg Protein binding @ 55% Elimination: > 90% renal Half-life @ 7 hrs (with normal CLcr) Vancomycin is not removed by standard HD or PD, but it is removed by CVVH Increased 34 fold from 0.3% to 7.9% NISS 1989-1993 Initially associated with ICU s Non ICU s Larger hospitals Lack of alterative therapy? Spread of genes involved to S. aureus and S. epidermidis Side effects of vancomycin: Red man syndrome - histamine-mediated erythematous flushing of the face, neck and trunk, a reaction which occurs during the infusion, and may be associated with hypotension. Nephrotoxicity and ototoxicity may occur in < 1% of pts especially those receiving other "toxic' drugs like aminoglycosides. A relationship between vancomycin level and nephrotoxicity or ototoxicity has not been established. It is now widely believed that the earlier reports of nephrotoxicity may have been related to impurities in the product. 6

Cephalosporins - what to remember Developed in response to clinical needs - Grouped by generation Learn properties of a prototype from each generation Extremely widely used - Safe - Side effects specific to individual members of the family as well as the family as a whole Not necessarily cross reaction with penicillin hypersensitivity Aztreonam - Gram negs - narrow Imipenem/Meropenem - everything except Vanco - need to know well 7